CMS Overview

We collaborate with global biotech/biopharma to jointly develop first- or best-in-class* innovative products and build a pharmaceutical ecosystem in a collaborative setting for the benefit of all stakeholders, whilst improving pharmaceutical R&D efficiency by accelerating the time to approval and increasing the likelihood of success.

We have a well-invested infrastructure and experienced teams to control key stages of the entire product life cycle, an extensive expert network covering various specialty fields, deep market understanding and a strong financial footing. Leveraging the above strengths, we are able to identify unmet clinical needs, as well as efficiently promote the clinical development and commercialization of innovative products. This continuing translation of scientific research into clinical practices has benefited patients over multiple decades and remains a core ambition.

We have been deeply involved in specialty therapeutic areas, such as cardio-cerebrovascular, gastroenterology, central nervous system, skin health, ophthalmology and pediatrics. We have gained leading academic and market positions for our major marketed products.

We have established independently operated specialty business lines to integrate resources across targeted therapeutic areas, building high-caliber, focused teams that drive expertise and performance. This model strengthens scale and efficiency in specialty businesses, so as to cultivate leadership in specialty fields. At the same time, we are extending our footprint into Southeast Asia and the Middle East, striving to become a “bridgehead” for global pharmaceutical companies to access Asia-Pacific emerging markets, and advancing the Group’s high-quality, sustainable growth.

*Best-in-class: innovative products with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems